FH-RCC | Search

Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

5,153 results for “FH-RCC”

Trials

View all 4392 →

Biomarkers of Response to Systemic Treatments in FH-deficient RCC

100 participants · First posted Feb 16, 2022

Molecular Markers in Predicting Response to Treatment in FH-deficient RCC Patients

100 participants · First posted Sep 10, 2022

Phase I/II Clinical Study of FH-006 for Injection in Patients With Malignant Solid Tumors

200 participants · First posted Dec 16, 2024

Drugs

View all 429 →

RCC-33

FH-2001

FH-006

Organizations

View all 22 →

FH ORTHO

France

RCC MEDICAL SUPPLY, INC.

United States

FH JOANNEUM Gesellschaft mbH

Austria

News

View all 310 →

Lenvatinib-Tislelizumab Combo Shows Promising 93% Response Rate in Rare Hereditary Kidney Cancer

Lenvatinib and Pembrolizumab Combination Shows Promise in Non-Clear Cell Renal Cell Carcinoma Subtypes

SABR Shows Promise in Renal Cell Carcinoma Management

Page 1 of 516